IPO of VERVE THERAPEUTICS, INC. will take place on June, 16 2021

VERVE THERAPEUTICS is a company focused on gene editing medicines, it is pioneering a new approach to the care of cardiovascular disease. Its goal is to disrupt today’s chronic care model for treating cardiovascular disease by providing a new therapeutic approach with single-course treatments in vivo.  

The most advanced programs of VERVE THERAPEUTICS target the genes PCSK9 and ANGPTL3, that were analysed as causes to reduce the level of blood lipids.  

It is supposed that the editing of these genes could noticeably lower the level of cholesterol for a long period of time during the life of people with ASCVD.  

The estimated valuation of the company after the IPO will be $412 million. 

The listed IPO bookrunners are JP Morgan, Jefferies, Guggenheim Securities и William Blair